The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis

Seminars in Cancer Biology

Volumn 13, Issue 1, 2003, Pages 83-89

  Pugh, Christopher William ^a   Ratcliffe, Peter John ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HIF; Hypoxia; Prolyl hydroxylase; Ubiquitin; Von Hippel Lindau tumour suppressor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; LIGASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TUMOR SUPPRESSOR PROTEIN;

CANCER; CARCINOGENESIS; GENE CONTROL; HYDROXYLATION; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; VON HIPPEL LINDAU DISEASE;

EID: 0037326037     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00103-7     Document Type: Article

References (78)

1. Kaelin W.G., Maher E.R. The VhL tumour-suppressor gene paradigm. Trends Genet. 14:1998;423-426.
2. Latif F., Tory K., Gnarra J., Yao M., Duh F.-M., Orcutt M.L.et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 260:1993;1317-1320.
3. Knudson A.G. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. U.S.A. 90:1993;10914-10921.
4. Iliopoulos O., Ohh M., Kaelin W.G. Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11661-11666.
5. Schoenfeld A., Davidowitz E.J., Burk R.D. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. USA. 95:1998;8817-8822.
6. Kibel A., Iliopoulos O., DeCaprio J.A., Kaelin W.G. Jr. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science. 269:1995;1444-1446.
7. Duan D.R., Pause A., Burgess W.H., Aso T., Chen D.Y.T., Garrett K.P.et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science. 269:1995;1402-1406.
8. Pause A., Lee S., Worrell R.A., Chen D.Y.T., Burgess W.H., Linehan W.M.et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. U.S.A. 94:1997;2156-2161.
9. Kamura T., Koepp D.M., Conrad M.N., Skowyra D., Moreland R.J., Iliopoulos O.et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 284:1999;657-661.
10. Ivan M., Kaelin W.G. The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev. 11:2001;27-34.
11. Semenza G.L., Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12:1992;5447-5454.
12. 2 tension. Proc. Natl. Acad. Sci. U.S.A. 92:1995;5510-5514.
13. 2 homeostasis. Curr. Opin. Genet. Dev. 8:1998;588-594.
14. Hoffman E.C., Reyes H., Chu F.-F., Sander F., Conley L.H., Brooks B.A.et al. Cloning of a factor required for activity of the Ah (Dioxin) receptor. Science. 252:1991;954-958.
15. Salceda S., Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. J. Biol. Chem. 272:1997;22642-22647.
16. Pugh C.W., O'Rourke J.F., Nagao M., Gleadle J.M., Ratcliffe P.J. Activation of hypoxia-inducible factor-1 definition of regulatory domains within the a subunit. J. Biol. Chem. 272:1997;11205-11214.
17. Huang L.E., Gu J., Schau M., Bunn H.F. Regulation of hypoxia-inducible factor 1α is mediated by an oxygen-dependent domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA. 95:1998;7987-7992.
18. O'Rourke J.F., Tian Y.-M., Ratcliffe P.J., Pugh C.W. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1α J. Biol. Chem. 274:1999;2060-2071.
19. Jewell U.R., Kvietikova I., Scheid A., Bauer C., Wenger R.H., Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 15:2001;1312-1314.
20. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21:2001;3995-4004.
21. Kallio P.J., Okamoto K., O'Brien S., Carrero P., Makino Y., Tanaka H.et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1α EMBO J. 17:1998;6573-6586.
22. Bhattacharya S., Michels C.L., Leung M.-K., Arany Z.P., Kung A.L., Livingston D.M. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1α Genes Dev. 13:1999;64-75.
23. Lando D., Pongratz I., Poellinger L., Whitelaw M.L. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1α and the HIF-like factor. J. Biol. Chem. 275:2000;4618-4627.
24. Lando D., Peet D.J., Whelan D.A., Gorman J.J., Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science. 295:2002;858-861.
25. Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K.et al. Molecular mechanisms of transcription activation by HLF and HIF-1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 18:1999;1905-1914.
26. Maxwell P.H., Wiesener M.S., Chang G.-W., Clifford S.C., Vaux E.C., Cockman M.E.et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275.
27. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C.et al. Hypoxia-inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275:2000;25733-25741.
28. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., Conaway J.W. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10430-10435.
29. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E.et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2:2000;423-427.
30. Tanimoto K., Makino Y., Pereira T., Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19:2000;4298-4309.
31. Bacon NC, Wappner P, O'Rourke JF, Bartlett SM, Shilo B, Pugh CW, et al. Regulation of the Drosophila Basic helix-loop-helix PAS protein Sima by hypoxia: functional evidence for homology with mammalian HIF-1 alpha. Biochem Biophys Res Commun 1998;249.
32. Woodward E.R., Hurst L.D., Clifford S.C., Affara N.A., Maher E.R. Comparative sequence analysis of the VHL tumour suppressor gene. Genomics. 65:2000;253-265.
33. Vaux E.C., Wood S.M., Cockman M.E., Nicholls L.G., Yeates K.M., Pugh C.W.et al. Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor. J. Biol. Chem. 12:2001;12.
34. Epstein A.C.R., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R.et al. C. elegans EGL-9 and mammalian homologues define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:2001;43-54.
35. 2 -regulated prolyl hydroxylation. Science. 292:2001;468-472.
36. 2 sensing. Science. 292:2001;464-468.
37. Yu F., White S.B., Zhao Q., Lee F.S. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. U.S.A. 98:2001;9630-9635.
38. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J. 20:2001;5197-5206.
39. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 294:2001;1337-1340.
40. Kivirikko K.I., Myllyharju J. Prolyl 4-hydroxylases and their protein disulfide isomerase subunit. Matrix Biol. 16:1998;357-368.
41. Schofield C.J., Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr. Opin. Struct. Biol. 9:1999;722-731.
42. Mahon P.C., Hirota K., Semenza G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15:2001;2675-2686.
43. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A.et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 287:2000;848-851.
44. Niemann S., Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet. 26:2000;268-270.
45. Astuti D., Latif F., Dallol A., Dahia P.L.M., Douglas F., George E.et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 69:2001;49-54.
46. Gimenez-Roqueplo A.-P., Favier J., Rustin P., Mourad J.-J., Plouin P.-F., Corvol P.et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet. 69:2001;1186-1197.
47. The Multiple Leiomyoma Consortium (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-10.
48. Kling P.J., Dragsten P.R., Roberts R.A., Santos B.D., Brooks D.J., Hedlund B.E.et al. Iron deprivation increases erythropoietin production in vitro in normal subjects and patients with malignancy. Br. J. Haematol. 95:1996;241-248.
49. Ebert B.L., Gleadle J.M., O'Rourke J.F., Bartlett S.M., Poulton J., Ratcliffe P.J. Isoenzyme specific regulation of genes involved in energy metabolism by hypoxia, cobalt and desferrioxamine: similarities with the regulation of erythropoietin. Biochem. J. 313:1995;809-814.
50. Seagroves T.N., Ryan H.E., Lu H., Wouters B.G., Knapp M., Thibault P.et al. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol. Cell. Biol. 21:2001;3436-3444.
51. Minchenko A., Leshchinsky I., Opentanova I., Sang N., Srinivas V., Armstead V.et al. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase-3 (PFKBF3) gene. Its possible role in the Warburg effect. J. Biol. Chem. 277:2002;6183-6187.
52. Warburg O. On the origin of cancer cells. Science. 123:1956;309-314.
53. Gleadle J.M., Ebert B.L., Firth J.D., Ratcliffe P.J. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am. J. Physiol. 268:1995;C1362-C1368.
54. Levy A.P., Levy N.S., Wegner S., Goldberg M.A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 270:1995;13333-13340.
55. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D.et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:1996;4604-4613.
56. Jiang B.H., Agani F., Passaniti A., Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57:1997;5328-5335.
57. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93:2001;266-276.
58. Wykoff C.C., Pugh C.W., Maxwell P.H., Harris A.L., Ratcliffe P.J. Identification of novel hypoxia-dependent and independent target genes of the von Hippel-Lindau (VHL) tumor suppressor by mRNA differential expression profiling. Oncogene. 19:2000;6297-6305.
59. Lal A., Peters H., Croix B.S., Haroon Z.A., Dewhirst M.W., Strausberg R.L.et al. Transcriptional response to hypoxia in human tumours. J. Natl. Cancer Inst. 93:2001;1337-1343.
60. Bruick R.K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. U.S.A. 97:2000;9082-9087.
61. Sowter H.M., Ratcliffe P.J., Watson P., Greenberg A.H., Harris A.L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61:2001;6669-6673.
62. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J.et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 94:1997;8104-8109.
63. Kung A.L., Wang S., Klco J.M., Kaelin W.G., Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6:2000;1335-1340.
64. Carmeliet P., Dor Y., Herbert J.-M., Fukumura D., Brusselmans K., Dewerchin M.et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490.
65. Ryan H.E., Lo J., Johnson R.S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17:1998;3005-3015.
66. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M.et al. Hypoxia-inducible factor-la is a positive factor in solid tumor growth. Cancer Res. 60:2000;4010-4015.
67. Schoenfeld A.R., Parris T., Eisenberger A., Davidowitz E.J., Leon M.D., Talasazan F.et al. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Oncogene. 19:2000;5851-5857.
68. Devarajan P., Leon M.D., Talasazan F., Schoenfeld A.R., Davidowitz E.J., Burk R.D. The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. J. Biol. Chem. 276:2001;40599-40605.
69. Pause A., Lee S., Lonergan K.M., Klausner R.D. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit on serum withdrawal. Proc. Natl. Acad. Sci. U.S.A. 95:1998;993-998.
70. Davidowitz E.J., Schoenfeld A.R., Burk R.D. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol. Cell. Biol. 21:2001;865-874.
71. Hoffman M.A., Ohh M., Yang H., Klco J.M., Ivan M., Kaelin W.G. Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10:2001;1019-1027.
72. Clifford S.C., Cockman M.E., Smallwood A.C., Mole D.R., Woodward E.R., Maxwell P.H., Ratcliffe P.J., Maher E.R. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10:2001;1029-1038.
73. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E.et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14:2000;391-396.
74. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.-M.et al. Modulation of hypoxia-inducible factor la expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60:2000;1541-1545.
75. Min J.H., Yang H., Ivan M., Gertler F., Kaelin W.G. Jr., Pavletich N.P. Structure of an HIF-l alpha -pVHL complex: hydroxyproline recognition in signaling. Science. 296:2002;1886-1889.
76. Hon W.C., Wilson M.I., Harlos K., Claridge T.D., Schofield C.J., Pugh C.W.et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature. 417:2002;975-978.
77. Hewitson K.S., McNeill L.A., Riordan M.V., Tian Y.M., Bullock A.N., Welford R.W.et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 277:2002;26351-26355.
78. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16:2002;1466-1471.